Andrea M. D'Armini
- Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension with distal lesionsBy Andrea M. D'Armini, Marco Morsolini, Gabriella Mattiucci, Valentina Grazioli, Nicola Vistarini and Roberto DoreAndrea M. D'Armini1Cardiac Surgery, University of Pavia, San Matteo Hospital, Pavia, ItalyMarco Morsolini1Cardiac Surgery, University of Pavia, San Matteo Hospital, Pavia, ItalyGabriella Mattiucci1Cardiac Surgery, University of Pavia, San Matteo Hospital, Pavia, ItalyValentina Grazioli1Cardiac Surgery, University of Pavia, San Matteo Hospital, Pavia, ItalyNicola Vistarini1Cardiac Surgery, University of Pavia, San Matteo Hospital, Pavia, ItalyRoberto Dore2Radiology, University of Pavia, San Matteo Hospital, Pavia, Italy
- Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 studyBy Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Nick H. Kim, Eckhard Mayer, Gerald Simonneau, Martin R. Wilkins, Tomás Pulido, Arno Fritsch, Neil Davie and Marius M. HoeperAndrea M. D'Armini1Division of Cardiac Surgery, IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani2Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyNick H. Kim3Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, United StatesEckhard Mayer4Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, GermanyGerald Simonneau5Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceMartin R. Wilkins6Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United KingdomTomás Pulido7Cardiopulmonary Department, National Heart Institute, Mexico City, MexicoArno Fritsch8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyMarius M. Hoeper9Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany
- An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2)By Gerald Simonneau, Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Gerrit Weimann and Eckhard MayerGerald Simonneau1Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAndrea M. D'Armini2Division of Cardiac Surgery, IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper4Clinic for Respiratory Medicine, Hannover Medical School, Hannover, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim6Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, United StatesChen Wang7Department of Respiratory Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin R. Wilkins8Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United KingdomArno Fritsch9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyGerrit Weimann9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyEckhard Mayer10Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extensionBy Gérald Simonneau, Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D'Armini2Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany4Dept of Medicine, Imperial College London, London, United KingdomFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center of Lung Research (DZL), Hannover, GermanyPavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California, San Diego, La Jolla,Chen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, United KingdomArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)By Eckhard Mayer, Andrzej Biederman, Andrea M. D'Armini, Ekkehard Grünig, Pavel Jansa, David P. Jenkins, Nick H. Kim, Walter Klepetko, Jaroslav Lindner, Michael M. Madani, Chen Wang, Neil Davie, Arno Fritsch and Hossein-Ardeschir GhofraniEckhard Mayer1Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, GermanyAndrzej Biederman2Department of Cardiac Surgery, Alendort Hospital, Warsaw, PolandAndrea M. D'Armini3Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, ItalyEkkehard Grünig4Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicDavid P. Jenkins6National Pulmonary Endarterectomy Service, Papworth Hospital, Cambridge, United KingdomNick H. Kim7Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, CA,Walter Klepetko8Department of Cardiothoracic Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, AustriaJaroslav Lindner92nd Surgical Department – Clinical Department of Cardiovascular Surgery, Charles University Prague, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicMichael M. Madani10Division of Cardiovascular and Thoracic Surgery, University of California San Diego Medical Center, San Diego, CA,Chen Wang11Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Department of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani13Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertensionBy Andrea M. D'ArminiAndrea M. D'ArminiDept of Cardio-Thoracic and Vascular Surgery, Heart and Lung Transplantation and Pulmonary Hypertension Unit, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, Italy
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.